Technology | Lung Cancer | May 09, 2018

Body Vision Medical Receives FDA Clearance for LungVision Tool

Lung navigation catheter part of LungVision Platform for early-stage lung cancer diagnostics and treatment procedures

Body Vision Medical Receives FDA Clearance for LungVision Tool

May 9, 2018 — Body Vision Medical received clearance from the U.S. Food and Drug Administration (FDA) to market their LungVision Tool. The LungVision Tool is an affordable lung navigation catheter with what the company calls superb maneuverability. It is used in conjunction with standard bronchoscopes and the LungVision System to guide endotherapy accessories to small pulmonary nodules.

This approval clears the way for Body Vision Medical to accelerate commercialization efforts for its LungVision Platform for pulmonary specialists across the U.S., providing an affordable and effective real-time solution for early-stage lung cancer diagnostics and treatment procedures.

The LungVison Imaging and Navigation System was cleared by the FDA in May 2017 and has been successfully used in over 290 clinical procedures in 10 lung cancer centers across the U.S.

"Body Vision has pioneered a new generation platform for navigation bronchoscopy that applies an augmented reality approach to plan, visualize and accurately track radiolucent bronchial nodules in real time," said Krish Bhadra, M.D., from CHI Memorial Hospital, Chattanooga, Tenn. "The LungVision navigation tool has clear performance and cost benefits over current navigation tools that are bound to electromagnetic sensing."

The clinical experience from a multicentral study with the LungVision System will be presented at the American Thoracic Society Conference, May 18-23 in San Diego.

For more information: www.bodyvisionmedical.com

 

Related Content

HealthMyne QIDS Platform Adds Cancer Screening Module
Technology | Clinical Decision Support | August 21, 2018
HealthMyne announced the release of Quantitative Imaging Decision Support (QIDS) 5 featuring a new, automated Cancer...
Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening
News | Lung Cancer | August 15, 2018
August 15, 2018 — Although national guidelines advise doctors to discuss the benefits and harms of...
ACR LI-RADS Steering Committee Releases New Version of CT/MRI LI-RADS
News | Clinical Decision Support | August 13, 2018
August 13, 2018 — The American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) steering commit
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Metro Health-University of Michigan Health Partners With Eon to Improve Lung Cancer Care
News | Oncology Diagnostics | August 07, 2018
Metro Health-University of Michigan Health announced it is partnering with healthcare data company Eon to improve the...
Gary D. Luker Named Editor of Radiology: Imaging Cancer

Image courtesy of University of Michigan Medical School

News | Oncology Diagnostics | August 06, 2018
The Board of Directors of the Radiological Society of North America (RSNA) announced that Gary D. Luker, M.D., will...
Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers
News | Lung Cancer | July 16, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Breast Cancer Studies Ignore Race, Socioeconomic Factors
News | Women's Health | July 11, 2018
A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help...
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Overlay Init